李莹, 杨俊兰. 乳腺癌内分泌治疗联用新型靶向药物研究进展[J]. 解放军医学院学报, 2013, 34(10): 1092-1094. DOI: 10.3969/j.issn.2095-5227.2013.10.032
引用本文: 李莹, 杨俊兰. 乳腺癌内分泌治疗联用新型靶向药物研究进展[J]. 解放军医学院学报, 2013, 34(10): 1092-1094. DOI: 10.3969/j.issn.2095-5227.2013.10.032
Advances in treatment of breast cancer with combined endocrine therapy and novel target agents[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2013, 34(10): 1092-1094. DOI: 10.3969/j.issn.2095-5227.2013.10.032
Citation: Advances in treatment of breast cancer with combined endocrine therapy and novel target agents[J]. ACADEMIC JOURNAL OF CHINESE PLA MEDICAL SCHOOL, 2013, 34(10): 1092-1094. DOI: 10.3969/j.issn.2095-5227.2013.10.032

乳腺癌内分泌治疗联用新型靶向药物研究进展

Advances in treatment of breast cancer with combined endocrine therapy and novel target agents

  • 摘要: 内分泌治疗是乳腺癌综合治疗的重要手段之一, 而内分泌治疗的耐药限制了其疗效, 对内分泌耐药机制的研究使人们认识到内分泌药物与一些靶向药物联合使用可能是克服耐药的有效方法。内分泌治疗联用新型靶向药物是近年来的研究热点, 本文就这方面的临床研究进展进行综述。

     

/

返回文章
返回